Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClear’s Scientific Advisory Board
August 06 2020 - 10:00AM
- Expert in Infectious Diseases and Immune
Oncology
- ViralClear Pharmaceuticals is Currently in Phase 2
Trials with Merimepodib in the Fight Against
COVID-19
BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the
“Company”) subsidiary, ViralClear Pharmaceuticals, Inc.
(ViralClear), today announced the addition of Professor Angus
Dalgleish to its Scientific Advisory Board (SAB).
Angus Dalgleish, M.D. is the Foundation Chair of Oncology and
Honorary Consultant in Medical Oncology at St. George’s University
and Hospital in London and Principal of the Institute of Cancer
Vaccines and Immunotherapy. He is a fellow of the Royal College of
Physicians both in the UK and Australia, the Royal College of
Pathologists, and the Academy of Medical Sciences (UK). Prof.
Dalgleish published seminal papers on human immunodeficiency virus
(HIV), its receptor on lymphocytes, and its pathogenesis.
“We are delighted to welcome Gus to our Scientific Advisory
Board with his breadth of experience in developing antiviral
drugs,” stated Jerome B. Zeldis, M.D., Ph.D., the acting Chief
Medical Officer and Head of ViralClear Pharmaceuticals, Inc. “Gus’
expertise will complement those who are already on the SAB, and we
look forward to working with him on this important mission.”
Professor Dalgleish said, “I am delighted to join the SAB of
ViralClear Pharmaceuticals with my long-term collaborator, friend
and colleague Jerry Zeldis with whom I worked with for several
years successfully developing lenalidomide and pomalidomide, and I
look forward to repeating this success against COVID-19.”
ViralClear recently announced the formation of its Scientific
Advisory Board to review all aspects of drug discovery and
development and advise the Company on its mission to control
emerging infections and viral diseases of special interest,
including COVID-19. Robin Robinson, Ph.D., the former Head of
Biomedical Advanced Research and Development Authority (BARDA), J.
Paul Waymack, M.D., ScD, formerly of the Food and Drug
Administration and a pioneer antiviral drug developer Michael
Sofia, Ph.D. were the first advisors appointed to the Board.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Merimepodib and ViralClear
BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary,
ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to
develop a novel pharmaceutical called merimepodib to treat patients
with COVID-19. Merimepodib is intended to be orally administered,
and has demonstrated broad-spectrum in vitro antiviral activity,
including strong activity against SARS-CoV-2 in cell cultures.
Merimepodib was previously in development as a treatment for
chronic hepatitis C and psoriasis by Vertex Pharmaceuticals
Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5
in phase 2) with over 400 subjects and patients and an extensive
preclinical safety package was completed.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024